• Imaging agents

Posluma Generic Name & Formulations

General Description

Flotufolastat F 18 (296–5846 MBq/mL [8–158 mCi/mL]); per ~25mL; soln for IV inj.

Pharmacological Class

Radioactive diagnostic agent.

How Supplied

Multi-dose vial (25mL)—1

Generic Availability


Mechanism of Action

Flotufolastat F 18 binds to PSMA expressed on cells, including prostate cancer cells, and is internalized. Prostate cancer cells usually overexpress PSMA. Fluorine-18 is a ß+ emitting radionuclide that can be detected using positron emission tomography.

Posluma Indications


For positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum PSA level.

Posluma Dosage and Administration


Give as IV bolus inj. 296MBq (8mCi); max volume 5mL (undiluted). Follow with NaCl 0.9% IV flush. Acquire images ~60mins after inj. The radiation absorbed dose from 296MBq (8mCi) dose is 4.1mSv.


Not established. 

Posluma Contraindications

Not Applicable

Posluma Boxed Warnings

Not Applicable

Posluma Warnings/Precautions


Risk of radiation exposure. Should only be used by trained and experienced physicians in the safe use and handling of radioactive materials to minimize radiation exposure. Risk for image misinterpretation and other errors; clinical correlation recommended. Contributes to patient's overall long-term cumulative radiation exposure. Advise to hydrate prior to and post-inj; void frequently after. Pregnancy, nursing mothers: not indicated for females. 

Posluma Pharmacokinetics

See Literature

Posluma Interactions


Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway may affect flotufolastat F 18 uptake. 

Posluma Adverse Reactions

Adverse Reactions

Diarrhea, BP increase, inj site pain. 

Posluma Clinical Trials

See Literature

Posluma Note

Not Applicable

Posluma Patient Counseling

See Literature